Oregon Health and Science University
This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.
Inclusion Criteria: 1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria. 2. Currently treated with levodopa at a minimum dose of 300 mg/day 3. Montreal Cognitive Assessment (MOCA) ≥15 4. Demonstrated capacity to provide informed consent. 5. 40-90 years of age 6. Estimated glomerular filtration rate ≥60 7. Absence of uncontrolled hypertension in medical history 8. Absence of insulin use Exclusion Criteria: \-
Folic Acid 1mg per day
Vitamin B6, 25mg per day
Vitamin B12, 1,000 ug per day
Arctuva estimate
Verify or correct the compensation shown for this listing.